News & Publications

The science, the data, and the story.

Press releases, media coverage, and peer-reviewed research documenting Blaze Bioscience's progress in fluorescence-guided surgery.

Press Releases

Company announcements

Official news and milestone announcements from Blaze Bioscience.

November 2, 2022
Clinical

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of Tozuleristide and the CANVAS® Imaging System in Pediatric Central Nervous System Tumors

Read press release →
April 7, 2020
Regulatory

Blaze Bioscience Announces FDA has Granted Fast Track Designation to BLZ-100 (Tozuleristide) for Pediatric Central Nervous System Tumors

Read press release →
May 9, 2019
Clinical

Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (Tozuleristide) in Adults with Glioma

Read press release →
Media

Coverage & features

Reporting on Blaze's science, clinical progress, and the people driving the mission.

PNAS
April 22, 2020
Venom Back in Vogue as a Wellspring for Drug Candidates
Read article ↗
Newsweek
May 10, 2019
Scorpion Venom Could Help to Detect Brain Tumors: Study
Read article ↗
Health Imaging
May 10, 2019
Novel Imaging Agent Utilizes Protein Found in Scorpion Venom
Read article ↗
Neurosurgery Now!
May 9, 2019
Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Gliomas
Read article ↗
Fierce Biotech
May 9, 2019
Blaze Bio Posts Phase 1 Data for Cancer-Illuminating 'Tumor Paint'
Read article ↗
GeekWire
May 9, 2019
Seattle Startup Makes Brain Tumors 'Light Up Like a Christmas Tree' in First Trial
Read article ↗
GeekWire
February 26, 2019
How Scorpion Venom Helps Improve Brain Cancer Surgery in Children by Making Tumors Glow
Read article ↗
Xconomy
February 20, 2019
Blaze Bio Raises $5M to Help Surgeons See Tumors From Healthy Tissue
Read article ↗
Seattle Children's Hospital
February 20, 2019
Lighting the Way for Children With Brain Tumors
Read article ↗
Publications

Peer-reviewed research

The scientific foundation underpinning tozuleristide and the Tumor Paint® technology.

2025
Lee A, Cole BL, Ojemann JG, Kittle DS, Perry JS, Parrish-Novak J, Miller DM, Hansen S, Harrington K, Ishak L, Gombotz C, Starr K, Poliachik SL, Leary SES
Phase 1 and expanded imaging study of tozuleristide in patients with pediatric primary central nervous system tumors
Journal of Neurosurgery: Pediatrics (2025). DOI: 10.3171/2025.5.PEDS24630
2025
Kittle DS, Harrington K, Novak J, Daly S, Jochheim C
Canvas® fluorescence imaging system characterization for intraoperative visualization of cancer cells with tozuleristide (BLZ-100) for a randomized, multi-center, phase 2/3 pediatric CNS tumor trial
SPIE Proceedings, Paper 13301-35 (2025)
2022
Crook ZR, Girard EJ, Sevilla GP, Brusniak M-Y, Rupert PB, Friend DJ, Gewe MM, Clarke M, Lin I, Ruff R, Pakiam F, Phi T-D, Bandaranayake A, Correnti CE, Mhyre AJ, Nairn NW, Strong RK, Olson JM
Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager
Science Translational Medicine 14, eabn0402 (2022). DOI: 10.1126/scitranslmed.abn0402
2021
Kobets AJ, Nauen D, Lee A, Cohen AR
Unexpected Binding of Tozuleristide "Tumor Paint" to Cerebral Vascular Malformations: A Potentially Novel Application of Fluorescence-Guided Surgery
Neurosurgery 89:204–211 (2021). DOI: 10.1093/neuros/nyab106
2021
Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients
Contemporary Clinical Trials Communications 23:100830 (2021). DOI: 10.1016/j.conctc.2021.100830
2020
Cook Sangar ML, Girard EJ, Hopping G, Yin C, Pakiam F, Brusniak M-Y, Nguyen E, Ruff R, Gewe MM, Byrnes-Blake K, Miller DM, Nairn NW, Mehlin C, Strand AD, Mhyre AJ, Correnti CE, Strong RK, Simon JA, Olson JM
A potent peptide-steroid conjugate accumulates in cartilage and reverses arthritis without evidence of systemic corticosteroid exposure
Science Translational Medicine 12, eaay1041 (2020). DOI: 10.1126/scitranslmed.aay1041
2020
Crook ZR, Nairn NW, Olson JM
Miniproteins as a Powerful Modality in Drug Development
Trends in Biochemical Sciences (2020). DOI: 10.1016/j.tibs.2019.12.008
2019
Patil R, Galstyan A, Sun T, Shatalova ES, Butte P, Mamelak AN, Carico C, Kittle DS, Grodzinski ZB, Chichi A, Ding H, Black KL, Ljubimova JY, Holler E
Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme
Biomaterials (2019). DOI: 10.1016/j.biomaterials.2019.03.029
2019
Dintzis SM, Hansen S, Harrington KM, Tan LC, Miller DM, Ishak L, Parrish-Novak J, Kittle D, Perry J, Gombotz C, Fortney T, Porenta S, Hales L, Calhoun KE, Anderson BO, Javid SH, Byrd DR
Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide
Archives of Pathology & Laboratory Medicine 143 (2019) 1076–1083. DOI: 10.5858/arpa.2018-0197-OA
2019
Patil CG, Walker DG, Miller DM, Butte P, Morrison B, Kittle DS, Hansen SJ, Nufer KL, Byrnes-Blake KA, Yamada M, Lin LL, Pham K, Perry J, Parrish-Novak J, Ishak L, Prow T, Black K, Mamelak AN
Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas
Neurosurgery 85 (2019) E641–E649. DOI: 10.1093/neuros/nyz125
2017
Parrish-Novak J, Byrnes-Blake K, Lalayeva N, Burleson S, Fidel J, Gilmore R, Gayheart-Walsten P, Bricker GA, Crumb WJ Jr, Tarlo KS, Hansen S, Wiss V, Malta E, Dernell WS, Olson JM, Miller DM
Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent
International Journal of Toxicology 36 (2017) 104–112. DOI: 10.1177/1091581817697685
2016
Baik FM, Hansen S, Knoblaugh SE, Sahetya D, Mitchell RM, Xu C, Olson JM, Parrish-Novak J, Mendez E
Fluorescence Identification of Head and Neck Squamous Cell Carcinoma and High-Risk Oral Dysplasia With BLZ-100, a Chlorotoxin–Indocyanine Green Conjugate
JAMA Otolaryngology – Head & Neck Surgery (2016). DOI: 10.1001/jamaoto.2015.3617
2015
Fidel J, Kennedy KC, Dernell WS, Hansen S, Wiss V, Stroud MR, Molho JI, Knoblaugh SE, Meganck J, Olson JM, Rice B, Parrish-Novak J
Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors
Cancer Research 75 (2015) 4283–4291. DOI: 10.1158/0008-5472.CAN-15-0471
2015
Parrish-Novak J, Holland EC, Olson JM
Image-guided tumor resection
Cancer Journal 21 (2015) 206–212. DOI: 10.1097/PPO.0000000000000113
2014
Kittle DS, Mamelak AN, Parrish-Novak J, Drazin D, Shweikeh F, Gangalum PR, Chesnokova A, Ljubimova JY, Black K
Fluorescence-Guided Tumor Visualization Using the Tumor Paint BLZ-100
Cureus 6(9):e210 (2014). DOI: 10.7759/cureus.210
2014
Butte PV, Mamelak A, Parrish-Novak J, Drazin D, Shweikeh F, Gangalum PR, Chesnokova A, Ljubimova JY, Black K
Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors
Neurosurgical Focus 36(2):E1 (2014). DOI: 10.3171/2013.11.FOCUS13497

Interested in our clinical research?

Learn more about the CANVAS® imaging system and the tozuleristide clinical program.

View Clinical Program